LumiThera Inc, a manufacturer of photobiomodulation (PBM) technologies that treat ocular damage and disease, has acquired Diopsys, Inc. a maker of electrophysiology (ERG) devices that analyze visual and neuro-visual disorders. The deal adds an established commercial U.S. sales force to LumiThera's EU sales team and a complimentary diagnostic and monitoring capability to LumiThera's PBM platform. LumiThera's device is being studied in the U.S. in patients with dry Age-related Macular Degeneration (AMD). Globally, the prevalence of AMD is estimated to grow by 20% to 243.3 million in 2030 from 195.6 million in 2020. Terms not announced.
Keywords: Healthcare Investment Banking, Healthcare M&A, Healthcare Mergers, Ophthalmology